Exploring the prognostic role of complex karyotype in chronic lymphocytic leukaemia patients treated with venetoclax-based regimens

被引：1
|
作者：
Serafin, Andrea [1 ]
Cellini, Alessandro [1 ]
Cavarretta, Chiara Adele [1 ]
Ruocco, Valeria [1 ]
Angotzi, Francesco [1 ]
Zatta, Ivan [1 ]
Frezzato, Federica [1 ]
Bonaldi, Laura [2 ]
Martines, Annalisa [2 ]
Pravato, Stefano [1 ]
Piazza, Francesco [1 ]
Trentin, Livio [1 ]
Visentin, Andrea [1 ]
机构：
[1] Univ Padua, Dept Med, Hematol Unit, Via Nicolo Giustiniani 2, I-35128 Padua, PD, Italy
[2] Veneto Inst Oncol, Immunol & Mol Oncol Unit, IOV IRCCS, Padua, Italy
来源：
BRITISH JOURNAL OF HAEMATOLOGY | 2024年 / 205卷 / 01期
关键词：
CK; high CK; MRD; venetoclax; CLL;
D O I：
10.1111/bjh.19517
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Although the unfavourable prognostic role of complex karyotype (CK) in chronic lymphocytic leukaemia (CLL) patients treated with chemoimmunotherapy has been clarified, its impact on the outcome of patients being treated with novel targeted agents, and especially with venetoclax-based regimens, remains to be resolved. In fact, only few studies, utilizing data derived from clinical trials (e.g. MURANO, CLL14, GAIA-CLL13), specifically focus on this topic while real-word evidence is missing. In our real-life retrospective study conducted on 61 patients with CLL and treated with venetoclax-based regimens in any therapeutic line, we documented a remarkable lower progression-free survival in patients harbouring both CK and high CK, while overall response rate (including complete remissions and partial remissions) and overall survival are not affected by CK in our population.
引用
收藏
页码：189 / 193
页数：5
相关论文
共 50 条
  • [21] Venetoclax in Patients with Previously Treated Chronic Lymphocytic Leukemia
    Roberts, Andrew W.
    Stilgenbauer, Stephan
    Seymour, John F.
    Huang, David C. S.
    CLINICAL CANCER RESEARCH, 2017, 23 (16) : 4527 - 4533
  • [22] High Karyotypic Complexity and Translocations Are Adverse Prognostic Features in Patients with Chronic Lymphocytic Leukemia without TP53 Aberrations Treated with Venetoclax-Based Time-Limited Combinations
    Furstenau, Moritz
    Thus, Yvonne
    Robrecht, Sandra
    Mellink, Clemens
    Van der Kevie-Kersemaekers, Anne-Marie
    Dubois, Julie M. N.
    Von Tresckow, Julia
    Patz, Michaela
    Gregor, Michael
    Thornton, Patrick
    Staber, Philipp B.
    Tadmor, Tamar
    Levin, Mark-David
    Da Cunha-Bang, Caspar
    Schneider, Christof
    Poulsen, Christian Bjorn
    Illmer, Thomas
    Schoettker, Bjorn
    Janssens, Ann
    Christiansen, Ilse
    Baumann, Michael
    Noesslinger, Thomas
    Regelink, Josien
    Dompeling, Ellen C.
    Lindstroem, Vesa
    Juliusson, Gunnar
    Widmer, Anouk
    Goede, Jeroen Simon
    Goldschmidt, Neta
    Simon, Florian
    De Silva, Nisha
    Fink, Anna-Maria
    Fischer, Kirsten
    Wendtner, Clemens-Martin
    Ritgen, Matthias
    Brueggemann, Monika
    Tausch, Eugen
    Stilgenbauer, Stephan
    Eldering, Eric
    Niemann, Carsten Utoft
    Hallek, Michael
    Eichhorst, Barbara
    Kreuzer, Karl-Anton
    Kater, Arnon P.
    BLOOD, 2022, 140
  • [23] Useful prognostic factors in patients with chronic lymphocytic leukaemia
    Troussard, X.
    IMMUNO-ANALYSE & BIOLOGIE SPECIALISEE, 2009, 24 (01): : 1 - 8
  • [24] Multilayer Profiling of MRD in Patients with Relapsed/Refractory CLL Treated with Venetoclax-Based Regimens in a Real-World Setting
    Pini, Katia
    Bruscaggin, Alessio
    Pirosa, Maria Cristina
    Forestieri, Gabriela
    de Almeida, Joyce Marques
    Stussi, Georg
    Oertli, Mathias
    Schmidt, Xenia
    Huelsenbeck, Johannes
    Noesslinger, Thomas
    Schwaner, Ingo
    Gallucci, Monica
    Simmons, Heidi
    Rossi, Davide
    Condoluci, Adalgisa
    BLOOD, 2023, 142
  • [25] Complex karyotype in patients with chronic lymphocytic leukemia.
    Yañez, L
    Cuadrado, MA
    Insunza, A
    Mesones, BG
    Bermudez, A
    Conde, E
    Bureo, E
    Iriondo, A
    BLOOD, 2005, 106 (11) : 328B - 328B
  • [26] The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia
    Visentin, Andrea
    Bonaldi, Laura
    Rigolin, Gian Matteo
    Mauro, Francesca Romana
    Martines, Annalisa
    Frezzato, Federica
    Imbergamo, Silvia
    Scomazzon, Edoardo
    Pravato, Stefano
    Bardi, Maria Antonella
    Cavallari, Maurizio
    Volta, Eleonora
    Cavazzini, Francesco
    Nanni, Maurizio
    Del Giudice, Ilaria
    Facco, Monica
    Guarini, Anna
    Semenzato, Gianpietro
    Foa, Robin
    Cuneo, Antonio
    Trentin, Livio
    BRITISH JOURNAL OF CANCER, 2019, 121 (02) : 150 - 156
  • [27] The combination of complex karyotype subtypes and IGHV mutational status identifies new prognostic and predictive groups in chronic lymphocytic leukaemia
    Andrea Visentin
    Laura Bonaldi
    Gian Matteo Rigolin
    Francesca Romana Mauro
    Annalisa Martines
    Federica Frezzato
    Silvia Imbergamo
    Edoardo Scomazzon
    Stefano Pravato
    Maria Antonella Bardi
    Maurizio Cavallari
    Eleonora Volta
    Francesco Cavazzini
    Maurizio Nanni
    Ilaria Del Giudice
    Monica Facco
    Anna Guarini
    Gianpietro Semenzato
    Robin Foà
    Antonio Cuneo
    Livio Trentin
    British Journal of Cancer, 2019, 121 : 150 - 156
  • [28] The complex karyotype and chronic lymphocytic leukemia: prognostic value and diagnostic recommendations
    Jondreville, Ludovic
    Krzisch, Daphne
    Chapiro, Elise
    Nguyen-Khac, Florence
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (11) : 1361 - 1367
  • [29] The prognostic role of CLLU1 in chronic lymphocytic leukaemia
    Smolej, Lukas
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2006, 77 (02) : 177 - 177
  • [30] Comparative efficacy of venetoclax-based regiments in the management of chronic lymphocytic leukemia: a systematic review and metanalysis
    Jamil, Abdur
    Aslam, Shehroz
    Riaz, Rida
    Qureshi, Zaheer
    Akram, Hamzah
    Kichloo, Asim
    Selene, Insija Ilyas
    ANNALS OF HEMATOLOGY, 2025,
12345